文献速递肝病消化道出血

内皮间质转化:肝硬化门静脉血栓的可靶向机制

Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis.
PubMed 文献 · Hepatology · 2025-10-06

研究分析肝硬化伴或不伴门静脉血栓(PVT)患者及供体门静脉组织,发现PVT与内膜偏心性增厚、细胞外基质堆积及细胞增多相关。PVT患者门静脉内皮细胞转录组显示内皮间质转化(EndMT)通路上调,他汀类药物在体外可减弱EndMT特征,提示其作为PVT治疗靶点的潜力。

要点

  • 肝硬化PVT与门静脉内膜偏心性增厚及细胞外基质堆积相关。
  • PVT患者门静脉内皮细胞中EndMT通路上调。
  • 他汀类药物在体外可减弱原代人门静脉内皮细胞的EndMT特征。

核心结论

  • 肝硬化门静脉内皮发生不良重构,以偏心性内膜增生为特征,由细胞外基质堆积及炎症和肌成纤维细胞样细胞浸润驱动,导致管腔狭窄并可能促进PVT。
  • EndMT在该转化中起关键作用,是新颖且有前景的治疗靶点,他汀类药物可减弱EndMT,凸显其在PVT治疗中的潜力。

研究设计与样本

  • 对肝硬化伴或不伴PVT患者移植肝门静脉组织及供体肝门静脉组织进行组织学分析。
  • 对PVT患者门静脉内皮细胞(PVEC)进行转录组分析,并行计算机药物重定位分析。
  • 体外用他汀类处理原代人PVEC,评估EndMT特征。

主要发现

  • PVT与内膜偏心性增厚相关,由细胞外基质物质堆积及内膜细胞增多导致。
  • PVT患者PVEC中EndMT通路上调。
  • 计算机药物重定位分析识别他汀类为潜在靶向这些改变的药物。
  • 体外他汀类处理减弱原代人PVEC的EndMT标志。

临床怎么用

  • 门静脉内皮EndMT可作为肝硬化PVT的潜在治疗靶点。
  • 他汀类药物可能用于减弱EndMT,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Portal vein thrombosis (PVT) is a frequent complication of cirrhosis, yet its pathophysiology remains elusive. Unlike thrombosis in other vascular beds, anticoagulation often fails to completely recanalize PVT, highlighting the need for greater mechanistic insight and alternative therapeutic approaches. Our study aimed to characterize the structural and cellular changes in the portal venous vascular bed to identify novel physiologically driven therapeutic targets. APPROACH AND RESULTS: Portal vein tissue specimens from explanted livers of patients with cirrhosis with and without PVT and from liver donors were histologically analyzed. PVT is associated with a remarkable eccentric thickening of the tunica intima due to accumulation of extracellular material and tunica intima increased cellularity. Transcriptomic analysis of human portal vein endothelial cells (PVEC) from patients with PVT identified the endothelial-to-mesenchymal transition (EndMT) pathway upregulated in PVECs from patients with PVT. In silico drug repurposing analysis identified statins as potential agents targeting these alterations. In vitro treatment with statins attenuated hallmarks of EndMT in primary human PVECs. CONCLUSIONS: In cirrhosis, the portal vein endothelium undergoes maladaptive remodeling marked by eccentric intimal hyperplasia, driven by ECM accumulation and infiltration of inflammatory and myofibroblast-like cells. This process narrows the lumen and may promote PVT. EndMT plays a key role in this transformation and emerges as a novel and promising therapeutic target. Notably, statins can attenuate EndMT, highlighting its potential in PVT treatment.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Anton A, Shalaby S, Botero ML, et al. Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis. Hepatology. 2025. PMID: 41144554. doi:10.1097/HEP.0000000000001547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。